Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.

ABSTRACT:

Importance

Systemic steroids are commonly used to manage immune-related adverse events (irAEs), but it remains unclear whether they may undermine immune checkpoint inhibitor (ICI) therapy outcomes. Few studies have assessed the impact of steroid timing and its association with continuation or cessation of ICI therapy.

Objective

To characterize how systemic steroids and steroid timing for irAEs are associated with survival in patients receiving ICI therapy.

Design, setting, and participants

This multicenter retrospective cohort study encompassed veterans receiving ICI for cancer between January 1, 2010, and December 31, 2021. Data analysis was conducted September 8, 2023.

Exposures

Identifiable primary diagnosis of cancer. Patients were categorized into 3 cohort

SUBMITTER: Van Buren I 

PROVIDER: S-EPMC10618850 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature